Journal ArticleDOI
Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis
W. Ian McDonald,A Compston,Gilles Edan,Donald E. Goodkin,Hans-Peter Hartung,Fred D. Lublin,Henry F. McFarland,Donald W. Paty,Chris H. Polman,Stephen C. Reingold,Magnhild Sandberg-Wollheim,William A. Sibley,Alan J. Thompson,Stanley van den Noort,Brian Y. Weinshenker,Jerry S. Wolinsky +15 more
Reads0
Chats0
TLDR
The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including “monosymptomatic” disease suggestive of MS, disease with a typical relapsing‐remitting course, and disease with insidious progression, without clear attacks and remissions.Abstract:
The International Panel on MS Diagnosis presents revised diagnostic criteria for multiple sclerosis (MS). The focus remains on the objective demonstration of dissemination of lesions in both time and space. Magnetic resonance imaging is integrated with dinical and other paraclinical diagnostic methods. The revised criteria facilitate the diagnosis of MS in patients with a variety of presentations, including "monosymptomatic" disease suggestive of MS, disease with a typical relapsing-remitting course, and disease with insidious progression, without clear attacks and remissions. Previously used terms such as "clinically definite" and "probable MS" are no longer recommended. The outcome of a diagnostic evaluation is either MS, "possible MS" (for those at risk for MS, but for whom diagnostic evaluation is equivocal), or "not MS."read more
Citations
More filters
Journal ArticleDOI
Natalizumab: alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS.
TL;DR: Preliminary efficacy results showed a marked reduction in the formation of new gadolinium-enhancing lesions and reduced the number of patients with relapse by 50% in patients with relapsing–remitting or secondary progressive multiple sclerosis receiving natalizumab versus those receiving placebo over a 6-month period.
Journal ArticleDOI
Acute Fulminant Demyelinating Disease: A Descriptive Study of 60 Patients
Jérôme De Seze,Marc Debouverie,Hélène Zéphir,Christine Lebrun,Frédéric Blanc,Véronique Bourg,Sandrine Wiertlewski,Sophie Pittion,David Laplaud,Emmanuelle Le Page,Romain Deschamps,Philippe Cabre,Jean Pelletier,Irina Malikova,Pierre Clavelou,Valérie Jaillon,Gilles Defer,Pierre Labauge,Olivier Gout,Clotilde Boulay,Gilles Edan,Patrick Vermersch +21 more
TL;DR: This study found some differences concerning the risk of evolution to clinically definite MS after a first demyelinating episode suggestive of ADEM, and proposed criteria that should now be tested in a larger, prospective cohort study.
Journal ArticleDOI
Proteomics of human cerebrospinal fluid: Discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics
Ann Cathrine Kroksveen,Jill A. Opsahl,Thin Thin Aye,Rune J. Ulvik,Rune J. Ulvik,Frode S. Berven +5 more
TL;DR: Some of the potential pitfalls in biomarker studies using CSF are focused on, the status of the field of CSF proteomics in general is summarized, and some of the most promising proteomics biomarker study approaches are discussed.
Journal ArticleDOI
Tobacco smoking and disability progression in multiple sclerosis: United Kingdom cohort study
Ali Manouchehrinia,Christopher R. Tench,Jonathan Maxted,Rashid H. Bibani,John Britton,Cris S. Constantinescu +5 more
TL;DR: The data suggest that regular smoking is associated with more severe disease and faster disability progression, and smoking cessation, whether before or after onset of the disease, isassociated with a slower progression of disability.
Journal ArticleDOI
Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management
TL;DR: A better understanding of pathological and pathogenetic processes in patients with a CIS will facilitate the development of disease-modifying treatments for patients with MS before they become disabled.
References
More filters
Journal ArticleDOI
New diagnostic criteria for multiple sclerosis: guidelines for research protocols.
Charles M. Poser,Donald W. Paty,Labe C. Scheinberg,W I McDonald,F A Davis,George C. Ebers,Kenneth P. Johnson,William A. Sibley,Donald H. Silberberg,Wallace W. Tourtellotte +9 more
TL;DR: Today there is a need for more exact criteria than existed earlier in order to conduct therapeutic trials in multicenter programs, to compare epidemiological surveys, to evaluate new diagnostic procedures, and to estimate the activity of the disease process in MS.
Journal ArticleDOI
The clinical course of neuromyelitis optica (Devic's syndrome)
TL;DR: Clinical, laboratory, and imaging features generally distinguish neuromyelitis optica from MS, and patients with relapsing optic neuritis and myelitis may have neuromyeliitis opticas rather than MS.
Journal ArticleDOI
Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis.
George A. Schumacher,Gilbert Beebe,Robert F. Kibler,Leonard T. Kurland,John F. Kurtzke,Fletcher McDowell,Benedict Nagler,William A. Sibley,Wallace W. Tourtellotte,Thomas L. Willmon +9 more
TL;DR: Since its etiology and pathogenesis have eluded detection, it is not surprising that therapeutic attempts have been empiric and often unscientific.
Journal ArticleDOI
Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis.
Frederik Barkhof,Massimo Filippi,David Miller,Philip Scheltens,Adriana Campi,Chris H. Polman,Giancarlo Comi,Herman J. Adèr,N. A. Losseff,Jacob Valk +9 more
TL;DR: It is concluded that a four-parameter dichotomized MRI model including gadolinium-enhancement, juxtacortical, infratentorial and periventricular lesions best predicts conversion to clinically definite multiple sclerosis.
Journal ArticleDOI
MRI in the diagnosis of MS A prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT
Donald W. Paty,Joel Oger,Lorne F. Kastrukoff,S. A. Hashimoto,John P. Hooge,Andrew Eisen,K. A. Eisen,S. J. Purves,M. D. Low,V. Brandejs,W. D. Robertson,David Kb Li +11 more
TL;DR: MRI was the best method for demonstrating dissemination in space and laboratory-supported definite MS (LSDMS) could be diagnosed in 85 patients of the total 200, and MRI predicted that diagnosis in 18/19 (95%).
Related Papers (5)
Rating neurologic impairment in multiple sclerosis An expanded disability status scale (EDSS)
Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria
Chris H. Polman,Stephen C. Reingold,Brenda Banwell,Michel Clanet,Jeffrey A. Cohen,Massimo Filippi,Kazuo Fujihara,Eva Havrdova,Michael Hutchinson,Ludwig Kappos,Fred D. Lublin,Xavier Montalban,Paul L. O’Connor,Magnhild Sandberg-Wollheim,Alan J. Thompson,Emmanuelle Waubant,Brian G. Weinshenker,Jerry S. Wolinsky +17 more